Clinical trial software provider Sophia Genetics has inked a partnership with AstraZeneca to improve clinical trials for new cancer treatments.
Sophia’s multimodal technology combines radiomics analysis of medical imaging data, molecular data, digital pathology, clinical and biologic data to better predict the best treatments for patients, the company said in a Feb. 13 press release. Together, AstraZeneca and Sophia are looking for ways to speed trials and improve clinical decision-making to ultimately get new and effective treatments to patients.
Financial details of the partnership weren’t disclosed.
“Multimodality aims to harness the power of advanced AI and machine learning models by integrating multiple data modalities to obtain key insights which inform prognosis and response to therapy at the individual patient level,” Greg Rossi, an AstraZeneca senior vice president, said in the release. “This approach is synergistic with AstraZeneca’s focus on developing personalized cancer treatment and has the potential to elevate precision oncology, currently driven by genomic-based biomarkers, into a truly multimodal connected health ecosystem.”
Additionally, Sophia announced the company launched its own real-world DEEP-Lung-IV clinical study to identify multimodal predictive signatures of response to immunotherapy for patients with advanced lung cancer.
Last March, Sophia signed a pact with Realm IDx to advance next-generation sequencing research for cancer. Under that deal, the two planned to combine Sophia’s data-driven medicine analytics platform with the genetic variant assessment database and range of diagnostic tests developed by Realm IDx subsidiary Ambry Genetics.